Literature DB >> 30190306

Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer.

Michael C Kreissl1, Marcel J R Janssen2, James Nagarajah3,4.   

Abstract

On successful completion of this activity one should be able to judge the prognosis of patients harboring metastasized differentiated thyroid cancer (DTC); identify suitable treatment regimens, taking into account the characteristics of the tumor and the patient's general condition; and know the basics of radioiodine treatment, tyrosine kinase treatment, and redifferentiation treatment for metastasized DTC.
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  metastasized thyroid cancer; radioiodine refractory thyroid cancer; redifferentiation; tyrosine kinase inhibitor

Mesh：

Year:  2018        PMID： 30190306     DOI： 10.2967/jnumed.117.190819

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  17 in total

1.  Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma.

Authors:  Xin-Yun Zhang; Jian-Wen Sun; Zhong-Ling Qiu; Yang Wang; Xiao-Yue Chen; Jin-Hua Zhao; Quan-Yong Luo
Journal:  Endocrine       Date:  2019-07-17       Impact factor: 3.633

2.  Effect of Kinase Inhibitors on the Technetium-99m Uptake into Thyroid Carcinoma Cells In Vitro.

Authors:  Anna Anschlag; Brandon H Greene; Lorianna KÖnneker; Markus Luster; James Nagarajah; Sabine WÄchter; Annette Wunderlich; Andreas Pfestroff
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

3.  Innovative analysis of distant metastasis in differentiated thyroid cancer.

Authors:  Danyang Chen; Lei Huang; Sichao Chen; Yihui Huang; Di Hu; Wen Zeng; Min Wang; Wei Zhou; Haifeng Feng; Wei Wei; Chao Zhang; Zeming Liu; Liang Guo
Journal:  Oncol Lett       Date:  2020-01-15       Impact factor: 2.967

4.  Long noncoding RNA FER1L4 promotes the malignant processes of papillary thyroid cancer by targeting the miR-612/ Cadherin 4 axis.

Authors:  Luyao Wu; Yu Ding; Houchao Tong; Xi Zhuang; Jingsheng Cai; Yan Si; Hao Zhang; Xiaoting Wang; Meiping Shen
Journal:  Cancer Cell Int       Date:  2021-07-21       Impact factor: 5.722

5.  Dynamin 2 Is Correlated with Recurrence and Poor Prognosis of Papillary Thyroid Cancer.

Authors:  Ning Ren; Zhenmin Tian; Hongmei Sun; Xiaofei Lu
Journal:  Med Sci Monit       Date:  2020-08-22

6.  MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAF V600E: An In Vitro Study.

Authors:  Hao Fu; Lingxiao Cheng; Yuchen Jin; Lin Cheng; Min Liu; Libo Chen
Journal:  Mol Ther Oncolytics       Date:  2019-02-05       Impact factor: 7.200

7.  Patients Aged ≥55 Years With Stage T1-2N1M1 Differentiated Thyroid Cancer Should Be Downstaged in the Eighth Edition AJCC/TNM Cancer Staging System.

Authors:  Zeming Liu; Sichao Chen; Yihui Huang; Di Hu; Min Wang; Wei Wei; Chao Zhang; Wen Zeng; Liang Guo
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

8.  Case Report: Management of an Elderly Patient With Metastatic Radioiodine-Resistant Differentiated Thyroid Cancer in a Rural Community, Remote From Specialist Oncology Services.

Authors:  Rachael Wybrew; Michael Loynd; Maria Wybrew; Leslie Samuel
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-01       Impact factor: 5.555

9.  Optimizing reconstruction parameters for quantitative 124I-PET in the presence of therapeutic doses of 131I.

Authors:  Louise M Fanchon; Bradley J Beattie; Keith Pentlow; Steven M Larson; John L Humm
Journal:  EJNMMI Phys       Date:  2021-07-12

10.  Circular RNA Circ_0067934 Attenuates Ferroptosis of Thyroid Cancer Cells by miR-545-3p/SLC7A11 Signaling.

Authors:  Hui-Hui Wang; Jia-Ni Ma; Xiao-Rong Zhan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-05       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.